tiprankstipranks
Trending News
More News >
Merck & Company (MRK)
NYSE:MRK
US Market

Merck & Company (MRK) Stock Forecast & Price Target

Compare
13,720 Followers
See the Price Targets and Ratings of:

MRK Analyst Ratings

Moderate Buy
17Ratings
Moderate Buy
9 Buy
7 Hold
1 Sell
Based on 17 analysts giving stock ratings to
Merck
& Company
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

MRK Stock 12 Month Forecast

Average Price Target

$101.47
▲(23.16%Upside)
Based on 17 Wall Street analysts offering 12 month price targets for Merck & Company in the last 3 months. The average price target is $101.47 with a high forecast of $138.00 and a low forecast of $82.00. The average price target represents a 23.16% change from the last price of $82.39.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"74":"$74","139":"$139","90.25":"$90.3","106.5":"$106.5","122.75":"$122.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":138,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$138.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":101.47,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$101.47</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":82,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$82.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[74,90.25,106.5,122.75,139],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,81.81,86.13230769230769,90.45461538461538,94.77692307692308,99.09923076923077,103.42153846153846,107.74384615384616,112.06615384615385,116.38846153846154,120.71076923076923,125.03307692307692,129.35538461538462,133.67769230769233,{"y":138,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,81.81,83.32230769230769,84.83461538461539,86.34692307692308,87.85923076923078,89.37153846153846,90.88384615384615,92.39615384615385,93.90846153846154,95.42076923076922,96.93307692307692,98.44538461538461,99.95769230769231,{"y":101.47,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,81.81,81.82461538461538,81.83923076923077,81.85384615384615,81.86846153846155,81.88307692307693,81.89769230769231,81.91230769230769,81.92692307692307,81.94153846153846,81.95615384615385,81.97076923076924,81.98538461538462,{"y":82,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":123.72,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110.1,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":114.58,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.74,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.21,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.98,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.65,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.55,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.26,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.43,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.49,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.81,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$138.00Average Price Target$101.47Lowest Price Target$82.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on MRK
TipRanks AITipRanks
Not Ranked
TipRanks
$94
Buy
14.09%
Upside
Reiterated
07/02/25
Merck & Company's stock score is driven by strong financial performance and attractive valuation metrics. The positive outlook from their earnings call and technical indicators suggest potential growth, although there are challenges such as declining sales in China and tariff impacts. The company's strategic focus on high-growth areas and a robust pipeline supports its long-term potential.
UBS
$105
Buy
27.44%
Upside
Reiterated
07/02/25
Merck & Company (MRK) Gets a Buy from UBS
Berenberg Bank Analyst forecast on MRK
Unknown AnalystBerenberg Bank
Not Ranked
Berenberg Bank
$100
Buy
21.37%
Upside
Reiterated
07/01/25
Berenberg Bank Reaffirms Their Buy Rating on Merck & Company (MRK)
TD Cowen Analyst forecast on MRK
Steve ScalaTD Cowen
TD Cowen
$100
Hold
21.37%
Upside
Reiterated
06/26/25
TD Cowen Sticks to Their Hold Rating for Merck & Company (MRK)
Citi
Hold
Reiterated
06/24/25
Citi Keeps Their Hold Rating on Merck & Company (MRK)
Morgan Stanley Analyst forecast on MRK
Terence FlynnMorgan Stanley
Morgan Stanley
$99
Hold
20.16%
Upside
Reiterated
06/23/25
Morgan Stanley Sticks to Their Hold Rating for Merck & Company (MRK)Morgan Stanley analyst Terrance Flynn reiterated an Equalweight rating and $99.00 price target on Merck (NYSE: MRK).
Bernstein
$95
Hold
15.31%
Upside
Reiterated
06/21/25
We rate MRK & PFE Market-Perform.
Jefferies Analyst forecast on MRK
Akash TewariJefferies
Jefferies
$138
Buy
67.50%
Upside
Reiterated
06/18/25
Positive Outlook on Merck & Co. Stock Amid Stability in Gardasil Dosing Recommendations
Goldman Sachs Analyst forecast on MRK
Asad HaiderGoldman Sachs
Goldman Sachs
$99
Sell
20.16%
Upside
Reiterated
06/18/25
Sell Rating for Merck & Company Amid Vaccine Policy Uncertainty and Strategic Delays
Wells Fargo Analyst forecast on MRK
Mohit BansalWells Fargo
Wells Fargo
$97
Hold
17.73%
Upside
Reiterated
06/17/25
Merck & Company (MRK) Gets a Hold from Wells Fargo
Cantor Fitzgerald Analyst forecast on MRK
Carter GouldCantor Fitzgerald
Cantor Fitzgerald
$85
Hold
3.17%
Upside
Reiterated
06/10/25
Merck & Company (MRK) Receives a Hold from Cantor Fitzgerald
Bank of America Securities Analyst forecast on MRK
Tim AndersonBank of America Securities
Bank of America Securities
$99
Buy
20.16%
Upside
Reiterated
06/06/25
Bank of America Securities Reaffirms Their Buy Rating on Merck & Company (MRK)
J.P. Morgan Analyst forecast on MRK
Chris SchottJ.P. Morgan
J.P. Morgan
Buy
Reiterated
06/03/25
Merck & Co.: Strong Buy Rating Backed by Promising Oncology Pipeline and Strategic Initiatives
BMO Capital Analyst forecast on MRK
Evan SeigermanBMO Capital
BMO Capital
$82
Hold
-0.47%
Downside
Reiterated
06/02/25
Merck & Company: Hold Rating Amid Short-Term Challenges and Strategic Uncertainties
DBS
$100
Buy
21.37%
Upside
Reiterated
05/30/25
Merck & Company: Strong Buy Rating Driven by Keytruda Success and Promising Pipeline Developments
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on MRK
TipRanks AITipRanks
Not Ranked
TipRanks
$94
Buy
14.09%
Upside
Reiterated
07/02/25
Merck & Company's stock score is driven by strong financial performance and attractive valuation metrics. The positive outlook from their earnings call and technical indicators suggest potential growth, although there are challenges such as declining sales in China and tariff impacts. The company's strategic focus on high-growth areas and a robust pipeline supports its long-term potential.
UBS
$105
Buy
27.44%
Upside
Reiterated
07/02/25
Merck & Company (MRK) Gets a Buy from UBS
Berenberg Bank Analyst forecast on MRK
Unknown AnalystBerenberg Bank
Not Ranked
Berenberg Bank
$100
Buy
21.37%
Upside
Reiterated
07/01/25
Berenberg Bank Reaffirms Their Buy Rating on Merck & Company (MRK)
TD Cowen Analyst forecast on MRK
Steve ScalaTD Cowen
TD Cowen
$100
Hold
21.37%
Upside
Reiterated
06/26/25
TD Cowen Sticks to Their Hold Rating for Merck & Company (MRK)
Citi
Hold
Reiterated
06/24/25
Citi Keeps Their Hold Rating on Merck & Company (MRK)
Morgan Stanley Analyst forecast on MRK
Terence FlynnMorgan Stanley
Morgan Stanley
$99
Hold
20.16%
Upside
Reiterated
06/23/25
Morgan Stanley Sticks to Their Hold Rating for Merck & Company (MRK)Morgan Stanley analyst Terrance Flynn reiterated an Equalweight rating and $99.00 price target on Merck (NYSE: MRK).
Bernstein
$95
Hold
15.31%
Upside
Reiterated
06/21/25
We rate MRK & PFE Market-Perform.
Jefferies Analyst forecast on MRK
Akash TewariJefferies
Jefferies
$138
Buy
67.50%
Upside
Reiterated
06/18/25
Positive Outlook on Merck & Co. Stock Amid Stability in Gardasil Dosing Recommendations
Goldman Sachs Analyst forecast on MRK
Asad HaiderGoldman Sachs
Goldman Sachs
$99
Sell
20.16%
Upside
Reiterated
06/18/25
Sell Rating for Merck & Company Amid Vaccine Policy Uncertainty and Strategic Delays
Wells Fargo Analyst forecast on MRK
Mohit BansalWells Fargo
Wells Fargo
$97
Hold
17.73%
Upside
Reiterated
06/17/25
Merck & Company (MRK) Gets a Hold from Wells Fargo
Cantor Fitzgerald Analyst forecast on MRK
Carter GouldCantor Fitzgerald
Cantor Fitzgerald
$85
Hold
3.17%
Upside
Reiterated
06/10/25
Merck & Company (MRK) Receives a Hold from Cantor Fitzgerald
Bank of America Securities Analyst forecast on MRK
Tim AndersonBank of America Securities
Bank of America Securities
$99
Buy
20.16%
Upside
Reiterated
06/06/25
Bank of America Securities Reaffirms Their Buy Rating on Merck & Company (MRK)
J.P. Morgan Analyst forecast on MRK
Chris SchottJ.P. Morgan
J.P. Morgan
Buy
Reiterated
06/03/25
Merck & Co.: Strong Buy Rating Backed by Promising Oncology Pipeline and Strategic Initiatives
BMO Capital Analyst forecast on MRK
Evan SeigermanBMO Capital
BMO Capital
$82
Hold
-0.47%
Downside
Reiterated
06/02/25
Merck & Company: Hold Rating Amid Short-Term Challenges and Strategic Uncertainties
DBS
$100
Buy
21.37%
Upside
Reiterated
05/30/25
Merck & Company: Strong Buy Rating Driven by Keytruda Success and Promising Pipeline Developments
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Merck & Company

1 Month
xxx
Success Rate
10/13 ratings generated profit
77%
Average Return
+2.06%
reiterated a xxx
rating 29 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 76.92% of your transactions generating a profit, with an average return of +2.06% per trade.
3 Months
xxx
Success Rate
9/13 ratings generated profit
69%
Average Return
+2.62%
reiterated a xxx
rating 29 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 69.23% of your transactions generating a profit, with an average return of +2.62% per trade.
1 Year
Tim AndersonBank of America Securities
Success Rate
8/13 ratings generated profit
62%
Average Return
+3.41%
reiterated a buy rating 29 days ago
Copying Tim Anderson's trades and holding each position for 1 Year would result in 61.54% of your transactions generating a profit, with an average return of +3.41% per trade.
2 Years
xxx
Success Rate
13/17 ratings generated profit
76%
Average Return
+12.13%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 76.47% of your transactions generating a profit, with an average return of +12.13% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MRK Analyst Recommendation Trends

Rating
Mar 25
Apr 25
May 25
Jun 25
Jul 25
Strong Buy
2
2
2
3
2
Buy
25
28
21
22
10
Hold
17
19
15
26
16
Sell
0
0
0
1
1
Strong Sell
0
0
0
0
0
total
44
49
38
52
29
In the current month, MRK has received 12 Buy Ratings, 16 Hold Ratings, and 1 Sell Ratings. MRK average Analyst price target in the past 3 months is 101.47.
Each month's total comprises the sum of three months' worth of ratings.

MRK Financial Forecast

MRK Earnings Forecast

Next quarter’s earnings estimate for MRK is $2.06 with a range of $1.93 to $2.19. The previous quarter’s EPS was $2.22. MRK beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 39.17% of the time in the same period. In the last calendar year MRK has Preformed in-line its overall industry.
Next quarter’s earnings estimate for MRK is $2.06 with a range of $1.93 to $2.19. The previous quarter’s EPS was $2.22. MRK beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 39.17% of the time in the same period. In the last calendar year MRK has Preformed in-line its overall industry.

MRK Sales Forecast

Next quarter’s sales forecast for MRK is $15.91B with a range of $15.57B to $16.81B. The previous quarter’s sales results were $15.62B. MRK beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 48.89% of the time in the same period. In the last calendar year MRK has Preformed in-line its overall industry.
Next quarter’s sales forecast for MRK is $15.91B with a range of $15.57B to $16.81B. The previous quarter’s sales results were $15.62B. MRK beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 48.89% of the time in the same period. In the last calendar year MRK has Preformed in-line its overall industry.

MRK Stock Forecast FAQ

What is MRK’s average 12-month price target, according to analysts?
Based on analyst ratings, Merck & Company’s 12-month average price target is 101.47.
    What is MRK’s upside potential, based on the analysts’ average price target?
    Merck & Company has 23.16% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is MRK a Buy, Sell or Hold?
          Merck & Company has a consensus rating of Moderate Buy which is based on 9 buy ratings, 7 hold ratings and 1 sell ratings.
            What is Merck & Company’s price target?
            The average price target for Merck & Company is 101.47. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $138.00 ,the lowest forecast is $82.00. The average price target represents 23.16% Increase from the current price of $82.39.
              What do analysts say about Merck & Company?
              Merck & Company’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 17 Wall Streets Analysts.
                How can I buy shares of MRK?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis